Morepen Laboratories Limited
NSE: MOREPENLAB BSE: MOREPENLAB
NSE
53.91
1.55 (2.96%)
Prev Close
52.36
Open Price
52.69
Volume
4,747,370
Today Low / High
52.37 / 54.36
52 WK Low / High
42 / 100.9
Range
51 - 57
BSE
53.87
1.58 (3.02%)
Prev Close
52.29
Open Price
52.7
Volume
370,585
Today Low / High
52.42 / 54.3
52 WK Low / High
41.66 / 100.8
Range
51 - 57
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 53.91 (target range: 51 - 57), reflecting a change of 1.55 (2.96028%). On the BSE, it is listed at 53.87 (target range: 51 - 57), showing a change of 1.58 (3.02161%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
52.69
2.32%
17 Apr
52.30
0.11%
16 Apr
52.38
-0.21%
15 Apr
51.00
2.73%
11 Apr
50.70
-0.99%
09 Apr
48.94
-1.29%
08 Apr
49.99
-1.52%
07 Apr
42.20
13.20%
04 Apr
52.97
-7.02%
03 Apr
50.82
3.78%
02 Apr
49.62
-0.20%
01 Apr
47.90
3.09%
28 Mar
49.00
-2.37%
27 Mar
47.36
2.51%
26 Mar
49.57
-4.24%
25 Mar
52.35
-5.29%
24 Mar
51.01
1.43%
Morepen Laboratories Limited Graph
Morepen Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Morepen Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 53.91, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 53.87 | 54.41 | 48.97 - 59.85 |
| 54.95 | 43.96 - 65.94 | ||
| 55.49 | 38.84 - 72.13 | ||
| Bearish Scenario | 53.87 | 53.33 | 48.00 - 58.66 |
| 52.79 | 42.23 - 63.35 | ||
| 52.25 | 36.58 - 67.93 |
Overview of Morepen Laboratories Limited
ISIN
INE083A01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
4,344,900
Market Cap
29,540,183,967
Last Dividend
0
Official Website
IPO Date
1996-01-01
DCF Diff
86.20
DCF
-33
Financial Ratios Every Investor Needs
Stock Dividend of MOREPENLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2002-09-18 | September 18, 02 | 0.6 | 0.6 | 2002-09-23 | 2002-10-08 | 2002-07-01 |
| 2001-09-03 | September 03, 01 | 0.2 | 0.2 | 2001-09-16 | 2001-10-01 | 2001-06-16 |
| 2001-01-24 | January 24, 01 | 0.5 | 0.5 | 2001-02-09 | 2001-03-01 | 2001-01-16 |
| 2000-08-18 | August 18, 00 | 0.1 | 0.5 | 2000-09-04 | 2000-10-01 | 2000-07-18 |
| 2000-04-28 | April 28, 00 | 0.6 | 3 | 2000-05-15 | 2000-06-01 | 2000-04-18 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,701.90 Cr | 1,083.52 Cr | 618.38 Cr | 0.3633 | 5.20 Cr | 83.57 Cr | 417.38 Cr | 96.16 Cr | 1.88 | 172.60 Cr | 0.0565 |
| 2023-03-31 | 1,417.53 Cr | 955.74 Cr | 461.79 Cr | 0.3258 | 3.07 Cr | 14.16 Cr | 56.08 Cr | 38.68 Cr | 0.77 | 85.67 Cr | 0.0273 |
| 2022-03-31 | 1,541.57 Cr | 1,060.94 Cr | 480.63 Cr | 0.3118 | 3.01 Cr | 14.19 Cr | 118.01 Cr | 101.68 Cr | 2.26 | 156.77 Cr | 0.0660 |
| 2021-03-31 | 1,175.37 Cr | 786.78 Cr | 388.59 Cr | 0.3306 | 5.65 Cr | 12.17 Cr | 98.17 Cr | 97.09 Cr | 2.16 | 128.45 Cr | 0.0826 |
| 2020-03-31 | 839.60 Cr | 561.95 Cr | 277.65 Cr | 0.3307 | 2.55 Cr | 14.55 Cr | 36.90 Cr | 33.58 Cr | 0.75 | 78.00 Cr | 0.0400 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 16.95 Cr | 1,293.21 Cr | 445.98 Cr | 847.2262 Cr | 29.00 Cr | 12.05 Cr | 248.59 Cr | 301.30 Cr | 1.54 Cr | 0.00 Cr | 0.00 Cr | 402.0446 Cr |
| 2023-03-31 | 21.67 Cr | 1,110.50 Cr | 358.05 Cr | 752.9081 Cr | 25.16 Cr | 3.50 Cr | 228.89 Cr | 184.01 Cr | 66.37 Cr | 34.20 Cr | -33.77 Cr | 321.1631 Cr |
| 2022-03-31 | 15.80 Cr | 1,070.05 Cr | 491.95 Cr | 578.5612 Cr | 18.57 Cr | 2.77 Cr | 275.85 Cr | 160.79 Cr | 180.51 Cr | 33.01 Cr | 0.06 Cr | 456.4569 Cr |
| 2021-03-31 | 41.39 Cr | 858.15 Cr | 433.86 Cr | 424.7498 Cr | 17.05 Cr | -24.34 Cr | 175.33 Cr | 131.24 Cr | 178.15 Cr | 0.00 Cr | 1.09 Cr | 403.8000 Cr |
| 2020-03-31 | 13.64 Cr | 663.46 Cr | 379.87 Cr | 284.0611 Cr | 13.47 Cr | -0.17 Cr | 138.48 Cr | 134.09 Cr | 162.25 Cr | 0.00 Cr | 1.09 Cr | 351.4436 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 73.3746 Cr | -83.3002 Cr | 5.2049 Cr | -7.9609 Cr | -4.7207 Cr | 16.9451 Cr | -71.3808 Cr | 96.1599 Cr | 3.8351 Cr | 0.0000 Cr | -19.7079 Cr |
| 2023-03-31 | -91.1706 Cr | -46.5093 Cr | 143.5431 Cr | -137.1426 Cr | 5.8632 Cr | 21.6658 Cr | -45.9720 Cr | 55.7553 Cr | 6.5951 Cr | 0.0000 Cr | 46.9678 Cr |
| 2022-03-31 | -57.7576 Cr | -31.6785 Cr | 63.8518 Cr | -125.1256 Cr | -25.5843 Cr | 15.8026 Cr | -67.3680 Cr | 126.7026 Cr | 1.5233 Cr | 0.0000 Cr | -100.5287 Cr |
| 2021-03-31 | 50.8257 Cr | -70.3507 Cr | 47.2728 Cr | 10.4273 Cr | 27.7478 Cr | 41.3869 Cr | -40.3984 Cr | 98.5115 Cr | 3.5776 Cr | -0.4892 Cr | -36.8500 Cr |
| 2020-03-31 | 11.0172 Cr | -12.4615 Cr | 5.4883 Cr | -6.0498 Cr | 4.0440 Cr | 13.6391 Cr | -17.0670 Cr | 39.1076 Cr | 1.5242 Cr | -0.4892 Cr | -44.2741 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 452.78 Cr | 290.65 Cr | 162.13 Cr | 0.3581 | 31.21 Cr | 26.69 Cr | 0.49 | 41.48 Cr | 0.0589 |
| 2024-09-30 | 437.73 Cr | 270.10 Cr | 167.63 Cr | 0.3830 | 42.21 Cr | 34.85 Cr | 0.65 | 49.06 Cr | 0.0796 |
| 2024-06-30 | 455.22 Cr | 345.77 Cr | 109.45 Cr | 0.2404 | 15.05 Cr | 36.17 Cr | 0.71 | 55.05 Cr | 0.0795 |
| 2024-03-31 | 360.11 Cr | 255.04 Cr | 105.07 Cr | 0.2918 | 8.58 Cr | 8.24 Cr | 0.17 | 52.62 Cr | 0.0229 |
| 2023-12-31 | 444.55 Cr | 272.04 Cr | 172.51 Cr | 0.3881 | 46.19 Cr | 31.99 Cr | 0.63 | 54.64 Cr | 0.0720 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 19.55 Cr | 184.67 Cr | 204.22 Cr | 0.00 Cr | 282.39 Cr | 1,092.98 Cr | 269.83 Cr | 1,562.25 Cr | 451.82 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 16.95 Cr | 0.00 Cr | 0.00 Cr | 16.95 Cr | 0.00 Cr | 0.00 Cr | -847.23 Cr |
| 2024-03-31 | 52.12 Cr | 49.55 Cr | 52.12 Cr | 324.94 Cr | 248.59 Cr | 889.04 Cr | 237.66 Cr | 1,293.21 Cr | 445.98 Cr |
| 2023-12-31 | -57.84 Cr | 115.69 Cr | 57.84 Cr | 0.00 Cr | 0.00 Cr | 57.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 23.29 Cr | 41.09 Cr | 64.37 Cr | 284.47 Cr | 230.83 Cr | 815.53 Cr | 213.21 Cr | 1,193.78 Cr | 405.25 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 36.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 28.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 31.99 Cr | 16.89 Cr | 0.00 Cr | 0.00 Cr | 16.89 Cr | 74.48 Cr | 57.59 Cr | 0.00 Cr | 16.89 Cr |
| 2023-09-30 | 21.26 Cr | 15.37 Cr | 0.00 Cr | 0.00 Cr | 15.37 Cr | 57.59 Cr | 42.22 Cr | 0.00 Cr | 15.37 Cr |
| 2023-06-30 | 14.63 Cr | 15.43 Cr | 0.00 Cr | 0.00 Cr | 15.43 Cr | 38.47 Cr | 23.04 Cr | 0.00 Cr | 15.43 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2000-11-07 | November 07, 00 | 5:1 |
| 1996-09-09 | September 09, 96 | 47:40 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
General Manager of Process Engineering & Technology Transfer
Mr. Bhola Prasad
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Vipul Kumar Srivastava
Gender: male
Year Born: 1985
Manager of Administration
Ms. Sunita Suri
Gender: female
Year Born: 1994
Chief Operating Officer of API
Ms. Amita Sharma
Gender: female
Year Born: 1966
Head of International Business Development
Mr. Kushal Suri
Gender: male
Year Born: 1989
Head of Medipath Division
Mr. Anubhav Suri
Gender: male
Year Born: 1987
Functional Head of Talent Acquisition & HRBP
Mr. Vikas Sharma
Gender: male
Year Born:
Chairman & MD
Mr. Sushil Suri B.Sc., F.C.A., FCA
Gender: male
Year Born: 1964
Whole-Time Director
Mr. Sanjay Suri
Gender: male
Year Born: 1968
Chief Financial Officer
Mr. Ajay Kumar Sharma
Gender: male
Year Born: 1967
FAQs about Morepen Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Sushil Suri B.Sc., F.C.A., FCA.
What is the current market price of the stock?
The current price is ₹53.91.
What is the 52-week price range?
The range is ₹42-100.9.
What is the market capitalization of the company?
The market capitalization is ₹2,954.02 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.72.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Morepen Laboratories Limited (ISIN: INE083A01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,954.02 crores and an average daily volume of 4,344,900 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.